MCID: SLV003
MIFTS: 38

Salivary Gland Disease

Categories: Endocrine diseases, Immune diseases, Oral diseases

Aliases & Classifications for Salivary Gland Disease

MalaCards integrated aliases for Salivary Gland Disease:

Name: Salivary Gland Disease 12 54 15
Salivary Gland Disorders 76 43
Salivary Gland Diseases 55 73
Non-Neoplastic Salivary Gland Disorder 73
Non-Neoplastic Salivary Gland Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10854
ICD9CM 35 527.8

Summaries for Salivary Gland Disease

NINDS : 54 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.  

MalaCards based summary : Salivary Gland Disease, also known as salivary gland disorders, is related to igg4-related disease and lacrimal gland mucoepidermoid carcinoma, and has symptoms including snoring, halitosis and oral manifestations. An important gene associated with Salivary Gland Disease is MAML2 (Mastermind Like Transcriptional Coactivator 2). The drugs Pilocarpine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, lymph node and tonsil, and related phenotypes are homeostasis/metabolism and limbs/digits/tail

MedlinePlus : 43 Your salivary glands are in your mouth. You have three pairs of major salivary glands and hundreds of small (minor) glands. They make saliva (spit) and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Problems with salivary glands can cause them to become irritated and swollen. You may have symptoms such as A bad taste in your mouth Difficulty opening your mouth Dry mouth Pain in your face or mouth Swelling of your face or neck Causes of salivary gland problems include infections, obstruction, or cancer. Problems can also be due to other disorders, such as mumps or Sjogren's syndrome.

Wikipedia : 76 Salivary gland diseases (SGD) are multiple and varied in... more...

Related Diseases for Salivary Gland Disease

Graphical network of the top 20 diseases related to Salivary Gland Disease:



Diseases related to Salivary Gland Disease

Symptoms & Phenotypes for Salivary Gland Disease

UMLS symptoms related to Salivary Gland Disease:


snoring, halitosis, oral manifestations

MGI Mouse Phenotypes related to Salivary Gland Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.7 ALKBH3 AMHR2 AREG CRTC1 CRTC3 CST5
2 limbs/digits/tail MP:0005371 9.1 CRTC3 CST5 CYLD ISL1 MC3R SLC25A3

Drugs & Therapeutics for Salivary Gland Disease

Drugs for Salivary Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 350)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pilocarpine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 54-71-7, 92-13-7 5910
2
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
3
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
5
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
6
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Not Applicable 9004-61-9 53477741
7
Cevimeline Approved Phase 4,Not Applicable 107233-08-9 83898 25137844
8 sodium fluoride Approved Phase 4,Not Applicable 7681-49-4
9
Allantoin Approved Phase 4,Not Applicable 97-59-6 204
10
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2 1177-87-3
13
Oxybutynin Approved, Investigational Phase 4,Phase 2 5633-20-5 4634
14
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 5881
15
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
16
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
17
Betaine Approved, Nutraceutical Phase 4,Not Applicable 107-43-7 247
18
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
19 Gallopamil Investigational Phase 4 16662-47-8
20 Rebamipide Investigational Phase 4,Phase 2,Not Applicable 90098-04-7
21 Muscarinic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
22 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Calcineurin Inhibitors Phase 4,Phase 2
27 Anti-Ulcer Agents Phase 4,Phase 2,Not Applicable
28 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antineoplastic Agents, Hormonal Phase 4,Phase 2
30 Hormones Phase 4,Phase 2,Not Applicable
31 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 glucocorticoids Phase 4,Phase 2
33 Dermatologic Agents Phase 4,Phase 2,Not Applicable
34 Cyclosporins Phase 4,Phase 2,Not Applicable
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Antifungal Agents Phase 4,Phase 2,Phase 1,Early Phase 1
38 Hormone Antagonists Phase 4,Phase 2,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
40 Antacids Phase 4,Phase 2,Not Applicable
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Not Applicable
42 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
43 Calcium, Dietary Phase 4,Not Applicable
44 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 DHEA (Dehydroepiandrosterone) Phase 4,Phase 2
47 Antioxidants Phase 4,Phase 2,Not Applicable
48 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Anticoagulants Phase 4,Not Applicable
50 Chelating Agents Phase 4,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 420)
# Name Status NCT ID Phase Drugs
1 Effect of Pilocarpine in Patients With Xerostomia Unknown status NCT02982577 Phase 4 Pilocarpine
2 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
5 Effects of Mucoprotective Product on Xerostomia Completed NCT01316393 Phase 4
6 Effect of Korean Red Ginseng (KRG) on Dry Mouth Completed NCT00911768 Phase 4
7 Evaluation of an Electro-stimulator for the Treatment of Xerostomia Completed NCT00509808 Phase 4
8 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
9 Comparison Between Rebamipide 2% Versus Autologous Serum Completed NCT03608761 Phase 4 Rebamipide
10 Quality of Life and Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
11 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
12 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
13 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
14 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
15 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
16 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
17 Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention Completed NCT00631358 Phase 4 Maxidex
18 A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment Completed NCT00438048 Phase 4 Artificial Saliva
19 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
20 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
21 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Recruiting NCT03540823 Phase 4
22 Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome Recruiting NCT03319420 Phase 4 LO2A eye drops;Systane Ultra UD
23 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Active, not recruiting NCT03762824 Phase 4
24 Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome Not yet recruiting NCT03711214 Phase 4
25 Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use Withdrawn NCT02522936 Phase 4 Biotene oral spray
26 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
27 Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye Unknown status NCT02257957 Phase 3 PRP injection;Standard care Hyaluronic acid eye drops
28 Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood Unknown status NCT02153515 Phase 3
29 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
30 Efficacy of Tocilizumab in Primary Sjögren's Syndrome. Unknown status NCT01782235 Phase 2, Phase 3 Tocilizumab;Placebo
31 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Unknown status NCT01489904 Phase 2, Phase 3
32 Treatment of Salivary Gland Hypofunction With Neuro- Electrostimulation Unknown status NCT01174329 Phase 2, Phase 3
33 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
34 Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults Completed NCT02610868 Phase 3 MYOBLOC
35 Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases Completed NCT02425176 Phase 2, Phase 3 Botulinum toxin A (BoNT-A) 50U;Botulinum toxin A (BoNT-A) 100U;Botulinum toxin A (BoNT-A) 200U
36 Metoclopramide as Treatment of Clozapine-induced Hypersalivation Completed NCT02222220 Phase 3 Metoclopramide;placebo
37 Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT01994109 Phase 3 MYOBLOC
38 Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity Completed NCT01652001 Phase 2, Phase 3 Malic Acid
39 Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation Completed NCT00534573 Phase 3 Amisulpride, Moclobemide
40 A Trial Looking at Treating Dry Mouth After Radiotherapy for Head and Neck Cancer Completed NCT02941276 Phase 3
41 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
42 Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients Completed NCT00168181 Phase 3 Salagen
43 Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas Completed NCT00158691 Phase 3 Ethyol
44 Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants Completed NCT02692599 Phase 3
45 A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503189 Phase 3 KCT-0809 ophthalmic solution;Placebo
46 A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503163 Phase 3 KCT-0809 ophthalmic solution
47 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
48 Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions Completed NCT02091739 Phase 3 IncobotulinumtoxinA (100 Units);IncobotulinumtoxinA (75 Units);Placebo
49 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
50 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3

Search NIH Clinical Center for Salivary Gland Disease

Genetic Tests for Salivary Gland Disease

Anatomical Context for Salivary Gland Disease

MalaCards organs/tissues related to Salivary Gland Disease:

41
Salivary Gland, Lymph Node, Tonsil, T Cells

Publications for Salivary Gland Disease

Articles related to Salivary Gland Disease:

(show top 50) (show all 99)
# Title Authors Year
1
Sialendoscopy in treating pediatric salivary gland disorders: a systematic review. ( 29204918 )
2018
2
Biomarkers in Autoimmune Salivary Gland Disorders: A Review. ( 28231569 )
2017
3
Diagnostic work-up in obstructive and inflammatory salivary gland disorders. ( 28516970 )
2017
4
Distinct BK polyomavirus non-coding control region (NCCR) variants in oral fluids of HIV- associated Salivary Gland Disease patients. ( 27085139 )
2016
5
Outcomes of interventional sialendoscopy for obstructive salivary gland disorders: an Italian multicentre study. ( 28177330 )
2016
6
Effectiveness and costs of sialendoscopy in pediatric patients with salivary gland disorders. ( 26010768 )
2015
7
Oral mucocele/ranula: Another human immunodeficiency virus-related salivary gland disease? ( 25446909 )
2014
8
Salivary gland disease in SjAPgren's syndrome: sialoadenitis to lymphoma. ( 24287195 )
2014
9
HIV-associated salivary gland disease - clinical or imaging diagnosis? ( 25187268 )
2014
10
Focused review of investigation, management and outcomes of salivary gland disease in specialty-specific journals. ( 24792858 )
2014
11
Sialoendoscopy in the management of salivary gland disorders--4 years experience. ( 24834589 )
2014
12
Salivary gland disorders. ( 25077394 )
2014
13
Salivary gland disorders. ( 25443682 )
2014
14
Is sialendoscopy an effective treatment for obstructive salivary gland disease? ( 23404254 )
2013
15
Natural killer cells regulate murine cytomegalovirus-induced sialadenitis and salivary gland disease. ( 22156514 )
2012
16
Sialendoscopy for the management of obstructive salivary gland disease: a systematic review and meta-analysis. ( 22710505 )
2012
17
Sialoendoscopy for the treatment of pediatric salivary gland disorders. ( 23069821 )
2012
18
Viruses and salivary gland disease (SGD): lessons from HIV SGD. ( 21441486 )
2011
19
Salivary gland disorders. ( 21094722 )
2011
20
Salivary gland disease. ( 20428015 )
2010
21
Diagnostic discussion. HIV-associated salivary gland disease (HIVSGD)-HIV related parotid cysts. ( 20443533 )
2010
22
HIV-associated salivary gland disease. ( 19608050 )
2009
23
Recent advances in the management of salivary gland disease. ( 19651463 )
2009
24
Clinical implications of the neck in salivary gland disease. ( 18603202 )
2008
25
A revolution in the management of obstructive salivary gland disease. ( 16512096 )
2006
26
Advances in the treatment of salivary gland disease. ( 17194041 )
2006
27
Modern management of obstructive salivary gland disease. ( 16479855 )
2004
28
Clinical conditions and lesions mimicking salivary gland disease: Part 2. ( 15633830 )
2004
29
Salivary gland disease in pediatric HIV patients: an update. ( 15272653 )
2004
30
Clinical conditions and lesions mimicking salivary gland disease, part 1. ( 15622887 )
2004
31
Diagnosis and treatment of salivary gland disorders. ( 15000634 )
2004
32
Salivary gland disease in HIV/AIDS and primary SjAPgren's syndrome: analysis of collagen I distribution and histopathology in American and African patients. ( 12969229 )
2003
33
The genu of the submandibular duct--is the angle significant in salivary gland disease? ( 11803383 )
2002
34
Diagnosing, managing, and preventing salivary gland disorders. ( 11991308 )
2002
35
Comparative study of MR sialography and digital subtraction sialography for benign salivary gland disorders. ( 12372736 )
2002
36
The role of MRI in facial swelling due to presumed salivary gland disease. ( 11718383 )
2001
37
Benign salivary gland disease. ( 11480124 )
2001
38
Diagnosing salivary gland disease. ( 11462349 )
2001
39
Imaging of salivary gland disease. ( 10670049 )
2000
40
Salivary gland disease in human immunodeficiency virus-positive women from the WIHS study. Women's Interagency HIV Study. ( 10846124 )
2000
41
Salivary gland disorders. Neoplastic and nonneoplastic. ( 9927970 )
1999
42
Bilateral and multicystic major salivary gland disease: a rare presentation of primary SjAPgren's syndrome. ( 10209623 )
1998
43
The surgical management of salivary gland disease of the sublingual gland and floor of mouth. ( 11905350 )
1998
44
Lupus erythematosus profundus around the salivary glands: a case resembling submandibular salivary gland disease. ( 9229369 )
1997
45
An association between salivary gland disease and serological abnormalities in SjAPgren's syndrome. ( 9385581 )
1997
46
Salivary gland disorders and heredity. ( 9028463 )
1997
47
A guide to salivary gland disorders. ( 9061151 )
1997
48
Common salivary gland disorders: an update. ( 9879252 )
1997
49
Methods for the diagnosis of salivary gland disorders. ( 11507468 )
1997
50
The usefulness and limitations of combined Tc-99m pertechnetate and Ga-67 citrate imaging of salivary gland disorders. ( 7895438 )
1995

Variations for Salivary Gland Disease

Expression for Salivary Gland Disease

Search GEO for disease gene expression data for Salivary Gland Disease.

Pathways for Salivary Gland Disease

GO Terms for Salivary Gland Disease

Biological processes related to Salivary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.17 CDK9 CRTC1 CRTC3 ISL1 MAML2 NFIB
2 positive regulation of CREB transcription factor activity GO:0032793 8.96 CRTC1 CRTC3

Molecular functions related to Salivary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cAMP response element binding protein binding GO:0008140 8.62 CRTC1 CRTC3

Sources for Salivary Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....